Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer

ABSTRACT: The feasibility of longitudinal metastatic biopsies for gene expression profiling in breast cancer is unexplored. Dynamic changes in gene expression can potentially predict efficacy of targeted cancer drugs. Patients enrolled in a phase III trial of metastatic breast cancer with sunitinib combined with docetaxel (SU+DOC) versus docetaxel alone (DOC) were offered to participate in a translational substudy comprising longitudinal fine needle aspiration biopsies (FNAB) and positron emission imaging before (T1) and two weeks after start of treatment (T2). Aspirated tumor material was used for microarray analysis, and treatment-induced changes (T2 versus T1) in gene expression and standardized uptake values were investigated. Twenty-one patients were included in the docetaxel ± sunitinib tria

ORGANISM(S): Homo sapiens

SUBMITTER: John Lövrot 

PROVIDER: E-GEOD-54323 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress